Mounjaro® & Weight Loss

Mounjaro is FDA-approved for type 2 diabetes, not weight loss. While tirzepatide produces substantial weight loss (as demonstrated in the SURMOUNT trials), prescribing Mounjaro off-label for weight management means your insurance is unlikely to cover it for that purpose. At PEAK, we prescribe Zepbound for patients whose primary goal is weight loss — it's the same tirzepatide molecule with the FDA-approved weight management indication and better insurance coverage pathways.

Both contain tirzepatide and are made by Eli Lilly. The key differences: Mounjaro is approved for type 2 diabetes, while Zepbound is approved for chronic weight management. Zepbound also has a separate FDA approval for treating obstructive sleep apnea in adults with obesity. Zepbound is additionally available in a lower-cost vial format for cash-pay patients. For a detailed comparison, see our Zepbound vs Mounjaro guide.

In most cases, no. Insurance plans match medications to their FDA-approved indications. Mounjaro's approved indication is type 2 diabetes, so a claim for weight management is likely to be denied. Zepbound carries the weight management indication, giving it a substantially better path to insurance coverage when prescribed for weight loss. PEAK accepts Anthem, Cigna, Aetna, UnitedHealthcare, Sentara, and TRICARE commercial plans, and does not accept Medicare or Medicaid plans. At PEAK, we verify your insurance benefits before your first visit and handle all prior authorization for you. If Zepbound isn't covered by your plan, we can discuss the Zepbound savings program or the cash-pay vial option.

The most common side effects of tirzepatide (whether as Mounjaro or Zepbound) are gastrointestinal: nausea, diarrhea, constipation, vomiting, and decreased appetite. Some patients also experience fatigue during the initial weeks. These effects are typically mild to moderate and tend to improve as your body adjusts to each dose level. The gradual titration schedule (starting at 2.5 mg and increasing every 4 weeks) is specifically designed to minimize side effects. Serious but rare risks include pancreatitis and thyroid C-cell tumors (seen in animal studies). Tirzepatide carries a boxed warning: it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Your PEAK clinician will review your complete medical history to ensure tirzepatide is appropriate for you.

If you take Mounjaro for diabetes and are happy with your blood sugar control and any incidental weight loss, there may be no clinical reason to switch. However, if weight management is your primary goal and you don't have type 2 diabetes, switching to Zepbound is the clinically and administratively appropriate step. You'll get the same medication with the FDA-approved weight loss indication, better insurance coverage for that purpose, and access to Eli Lilly's Zepbound savings programs. Since both products contain identical tirzepatide, the switch is straightforward — your clinician simply transitions your prescription at the same dose.

Mounjaro contains tirzepatide, which activates both GIP and GLP-1 receptors. Wegovy and Ozempic contain semaglutide, which activates only the GLP-1 receptor. The dual-receptor approach has shown greater average weight loss in clinical trials. In terms of product lines: Mounjaro and Ozempic are the diabetes versions, while Zepbound and Wegovy are the weight loss versions. At PEAK, we prescribe Zepbound or Wegovy depending on which is the best fit for your health profile and insurance coverage. See our comparisons: Zepbound vs Wegovy.